GlobeNewswire BiotechnologyQwen · 实盘不做把握 9/10不做原因:不是事件
北京时间·🕒 发布 20:00:00·⟳ 抓取 20:01:47·⚡ 决策 09-01 20:10:54 +9m07s·56.3 天前
ProMIS Neurosciences 宣布参加2026年9月多场投资者会议，无新增临床或商业数据
会议参会公告是上市公司最常规的IR活动之一，不含任何新增临床数据、监管决定、订单或财务指引变化。文中提及的6个月中期数据为2026年7月已公开的历史信息，12个月数据预计2027年初仅为时间线提醒。无论Web、KB还是行情都无法从这类公告中提取可交易催化。
📄 原文GlobeNewswire Biotechnology↗ 原文
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechno…
不做 ProMIS Neurosciences（PMN.US）
会议参会公告为最常规的IR活动，不含新增临床数据、监管进展或商业催化；7月已公开的6个月中期数据是历史信息，12个月数据要到2027年初；事件无方向、无增量、无可交易edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ProMIS Neurosciences于2026年9月1日发布会议参会日程，涵盖Cantor、H.C. Wainwright等5场9月投资者会议。这是标准IR日程公告，不含新临床数据（7月中期数据为已知信息）、监管进展或商业里程碑。事件方向中性，无增量信息，无正期望交易机会。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,843 ms
{"result": "search_processed_events:agent query=`pmn investor events september 2026 | promis cantor h.c. wainwright conference | promis neurosciences conference participation`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 62.4/72 小时、2202 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 3,082 字
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.
Conference details below:
September 9-11: Cantor Global Healthcare Conference
Location: New York, NY
Fireside Chat: Wednesday, September 9, 9:10-9:40 a.m. ET
Participants: Pete Stavropoulos, Cantor analyst, and Neil Warma, ProMIS President & Chief Executive Officer
Webcast link:
Click Here
September 9-10: Moody Capital Disruptive Growth & Life Sciences Conference
Location: New York, NY
Presentation: Thursday, September 10, 1:45-2:05 p.m. ET, Room 1
Webcast link:
Click Here
September 14-16: H.C. Wainwright 28
th
Annual Global Investment Conference
Location: New York, NY
Presentation: Tuesday, September 15, 10:30-11:00 a.m. ET, Louis Room (4
th
floor)
Webcast link:
Click Here
September 21 (World Alzheimer’s Day): ProMIS Neurosciences and Nasdaq mark World Alzheimer’s Day at the Nasdaq Tower
Location: Nasdaq Tower, New York, NY
September 29: Roth Healthcare Opportunities Conference
Location: New York, NY
During these conferences, Neil Warma, President & Chief Executive Officer of ProMIS Neurosciences, Dr. Larry Altstiel, Chief Medical Officer, and Carie Pierce, VP, Investor Relations & External Affairs, will discuss the Company’s EpiSelect™ platform, its differentiated approach to developing therapeutics for neurodegenerative diseases driven by toxic misfolded proteins, and PMN310, the Company’s lead candidate in the ongoing PRECISE-AD Phase 1b trial in early Alzheimer’s disease.
ProMIS reported blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in patients with early AD in July 2026, with 12-month topline data anticipated in early 2027.
Webcast replays of the upcoming presentations, as well as a replay of the interim data webinar, will be available in the Investors section of the website.
Click Here
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
Investor Relations Contact:
Carie Pierce, VP, Investor Relations & External Affairs
IR@promisneurosciences.com
Conference details below:
September 9-11: Cantor Global Healthcare Conference
Location: New York, NY
Fireside Chat: Wednesday, September 9, 9:10-9:40 a.m. ET
Participants: Pete Stavropoulos, Cantor analyst, and Neil Warma, ProMIS President & Chief Executive Officer
Webcast link:
Click Here
September 9-10: Moody Capital Disruptive Growth & Life Sciences Conference
Location: New York, NY
Presentation: Thursday, September 10, 1:45-2:05 p.m. ET, Room 1
Webcast link:
Click Here
September 14-16: H.C. Wainwright 28
th
Annual Global Investment Conference
Location: New York, NY
Presentation: Tuesday, September 15, 10:30-11:00 a.m. ET, Louis Room (4
th
floor)
Webcast link:
Click Here
September 21 (World Alzheimer’s Day): ProMIS Neurosciences and Nasdaq mark World Alzheimer’s Day at the Nasdaq Tower
Location: Nasdaq Tower, New York, NY
September 29: Roth Healthcare Opportunities Conference
Location: New York, NY
During these conferences, Neil Warma, President & Chief Executive Officer of ProMIS Neurosciences, Dr. Larry Altstiel, Chief Medical Officer, and Carie Pierce, VP, Investor Relations & External Affairs, will discuss the Company’s EpiSelect™ platform, its differentiated approach to developing therapeutics for neurodegenerative diseases driven by toxic misfolded proteins, and PMN310, the Company’s lead candidate in the ongoing PRECISE-AD Phase 1b trial in early Alzheimer’s disease.
ProMIS reported blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in patients with early AD in July 2026, with 12-month topline data anticipated in early 2027.
Webcast replays of the upcoming presentations, as well as a replay of the interim data webinar, will be available in the Investors section of the website.
Click Here
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
Investor Relations Contact:
Carie Pierce, VP, Investor Relations & External Affairs
IR@promisneurosciences.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。